EA201690447A1 - БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ - Google Patents
БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯInfo
- Publication number
- EA201690447A1 EA201690447A1 EA201690447A EA201690447A EA201690447A1 EA 201690447 A1 EA201690447 A1 EA 201690447A1 EA 201690447 A EA201690447 A EA 201690447A EA 201690447 A EA201690447 A EA 201690447A EA 201690447 A1 EA201690447 A1 EA 201690447A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bispecific monovalent
- diabodies
- gpa33
- epitope
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
Настоящее изобретение относится к биспецифическим моновалентным диателам, которые содержат две полипептидные цепи и которые характеризуются наличием по меньшей мере одного сайта связывания, специфического в отношении эпитопа CD3, и одного сайта связывания, специфического в отношении эпитопа gpA33 (т.е. "gpA33 × CD3 биспецифическое моновалентное диатело"). Настоящее изобретение также относится к биспецифическим моновалентным диателам, которые содержат домен Fc иммуноглобулина ("биспецифические моновалентные Fc диатела") и состоят из трех полипептидных цепей и которые характеризуются наличием по меньшей мере одного сайта связывания, специфического в отношении эпитопа gpA33, и одного сайта связывания, специфического в отношении эпитопа CD3 (т.е. "gpA33 × CD3 биспецифическое моновалентное Fc-диатело"). Биспецифические моновалентные диатела и биспецифические моновалентные Fc-диатела согласно настоящему изобретению способны одновременно связываться с gpA33 и CD3. Настоящее изобретение относится к фармацевтическим композициям, которые содержат такие биспецифические моновалентные диатела или такие биспецифические моновалентные Fc-диатела. Настоящее изобретение дополнительно относится к способам применения таких диател в лечении злокачественной опухоли и других заболеваний и состояний.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361869528P | 2013-08-23 | 2013-08-23 | |
US201361907691P | 2013-11-22 | 2013-11-22 | |
EP13198859.4A EP2840091A1 (en) | 2013-08-23 | 2013-12-20 | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
PCT/US2014/051793 WO2015026894A2 (en) | 2013-08-23 | 2014-08-20 | Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201690447A1 true EA201690447A1 (ru) | 2016-08-31 |
EA036236B1 EA036236B1 (ru) | 2020-10-16 |
Family
ID=49882883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690447A EA036236B1 (ru) | 2013-08-23 | 2014-08-20 | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ |
Country Status (25)
Country | Link |
---|---|
US (2) | US9932400B2 (ru) |
EP (2) | EP2840091A1 (ru) |
JP (1) | JP6581985B2 (ru) |
KR (1) | KR102269584B1 (ru) |
CN (1) | CN105658235B (ru) |
AP (1) | AP2016009082A0 (ru) |
AU (1) | AU2014308907B2 (ru) |
BR (1) | BR112016003369A2 (ru) |
CA (1) | CA2920117C (ru) |
CL (1) | CL2016000363A1 (ru) |
CR (1) | CR20160090A (ru) |
EA (1) | EA036236B1 (ru) |
ES (1) | ES2827226T3 (ru) |
GE (1) | GEP20197033B (ru) |
HK (1) | HK1226000A1 (ru) |
IL (1) | IL244238B (ru) |
MX (1) | MX2016001738A (ru) |
MY (1) | MY179866A (ru) |
PE (1) | PE20160193A1 (ru) |
PH (1) | PH12016500291A1 (ru) |
SG (1) | SG11201601270WA (ru) |
TN (1) | TN2016000052A1 (ru) |
TW (1) | TWI675845B (ru) |
UA (1) | UA119329C2 (ru) |
WO (1) | WO2015026894A2 (ru) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
BR112016027912A2 (pt) | 2014-05-29 | 2018-02-20 | Macrogenics, Inc. | molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
BR112017005988A2 (pt) | 2014-09-26 | 2017-12-19 | Macrogenics Inc | diacorpo de fc monovalente biespecífico cd19 x cd3 capaz de realizar ligação específica a cd19 e a cd3, complexo polipeptídico covalentemente associado, composição farmacêutica, e uso da composição farmacêutica |
SG11201702544WA (en) | 2014-09-29 | 2017-04-27 | Univ Duke | Bispecific molecules comprising an hiv-1 envelope targeting arm |
WO2016149695A1 (en) | 2015-03-19 | 2016-09-22 | Duke University | HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES) |
WO2016149710A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
CA2979708A1 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
WO2016149698A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies) |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
EP3310811B1 (en) * | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
EP3328419B1 (en) | 2015-07-30 | 2021-08-25 | MacroGenics, Inc. | Pd-1-binding molecules and methods of use thereof |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
EP3370771A4 (en) * | 2015-11-03 | 2019-06-19 | Ambrx, Inc. | ANTI-CD3-FOLATE CONJUGATES AND USES THEREOF |
AU2016370376B2 (en) | 2015-12-14 | 2023-12-14 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
EP3405492B1 (en) | 2016-01-21 | 2020-10-21 | Novartis AG | Multispecific molecules targeting cll-1 |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
UY37127A (es) | 2016-02-17 | 2017-08-31 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
CN107556387A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用 |
WO2018053328A1 (en) * | 2016-09-16 | 2018-03-22 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
CN107915776B (zh) * | 2016-10-11 | 2021-05-14 | 康梦实 | 双特异性抗体fitc×cd3及其制备方法和应用 |
EP3585431A4 (en) | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
KR20200005732A (ko) | 2017-04-11 | 2020-01-16 | 인히브릭스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법 |
CN108728464A (zh) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | 一种表达抗hiv双特异性抗体的微环dna载体及其制备方法和应用 |
JP7303802B2 (ja) * | 2017-09-23 | 2023-07-05 | メモリアル スローン ケタリング キャンサー センター | A33抗体組成物および放射性免疫療法におけるその使用方法 |
CA3085432A1 (en) * | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd16-binding molecules and their use in the treatment of disease |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
CA3096123A1 (en) * | 2018-04-11 | 2019-10-17 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
WO2019233842A1 (en) * | 2018-06-08 | 2019-12-12 | F. Hoffmann-La Roche Ag | Peptidic linker with reduced post-translational modification |
CN112513081A (zh) * | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
US20220281998A1 (en) * | 2019-08-28 | 2022-09-08 | Azusapharma Sciences, Inc. | Bifidobacterium spp. expressing and secreting diabody-type bsab |
MX2022007158A (es) | 2019-12-13 | 2022-07-11 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso. |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
US4752601A (en) | 1983-08-12 | 1988-06-21 | Immunetech Pharmaceuticals | Method of blocking immune complex binding to immunoglobulin FC receptors |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5985599A (en) | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US4800078A (en) | 1987-05-28 | 1989-01-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
GB8916400D0 (en) | 1989-07-18 | 1989-09-06 | Dynal As | Modified igg3 |
AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
WO1991006287A1 (en) | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Protein microspheres and methods of using them |
US5364930A (en) | 1990-10-16 | 1994-11-15 | Northwestern University | Synthetic C1q peptide fragments |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
EP0583356B1 (en) | 1991-05-01 | 2002-07-31 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5223408A (en) | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
ZA94916B (en) | 1993-02-10 | 1995-08-10 | Unilever Plc | Immobilized proteins with specific binding capacities and their use in processes and products |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
AU7516694A (en) | 1993-07-30 | 1995-02-28 | Affymax Technologies N.V. | Biotinylation of proteins |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
CA2190101A1 (en) | 1994-05-13 | 1995-11-23 | Donald Leonard Nicholas Cardy | Improvements in or relating to peptide delivery |
CA2207961A1 (en) | 1995-01-05 | 1996-07-11 | Robert J. Levy | Surface-modified nanoparticles and method of making and using same |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
CA2230494A1 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
JP2000503204A (ja) * | 1996-01-08 | 2000-03-21 | ジェネンテック インコーポレーテッド | Wsxレセプター及びリガンド類 |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US5942328A (en) | 1996-02-29 | 1999-08-24 | International Business Machines Corporation | Low dielectric constant amorphous fluorinated carbon and method of preparation |
WO1997032572A2 (en) | 1996-03-04 | 1997-09-12 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
JP2001506967A (ja) | 1996-08-02 | 2001-05-29 | ブリストル―マイヤーズ・スクイブ・カンパニー | 治療およびインビボ診断における免疫グロブリンの使用の結果としての免疫グロブリン誘発毒性の抑制方法 |
US6025485A (en) | 1997-02-14 | 2000-02-15 | Arcaris, Inc. | Methods and compositions for peptide libraries displayed on light-emitting scaffolds |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
JP3884484B2 (ja) | 1997-01-16 | 2007-02-21 | マサチューセッツ インスティチュート オブ テクノロジー | 吸入用粒子の調製 |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
CZ20003099A3 (cs) | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek |
US6455263B2 (en) | 1998-03-24 | 2002-09-24 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using FACS |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
SE9802213D0 (sv) | 1998-06-18 | 1998-06-18 | Amersham Pharm Biotech Ab | A method for the removal/purification of serum albumins and means for use in the method |
DE69907456T2 (de) | 1998-06-24 | 2004-03-25 | Advanced Inhalation Research, Inc., Cambridge | Grosse poröse partikel ausgestossen von einem inhalator |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
EP1141024B1 (en) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
DE19937264A1 (de) | 1999-08-06 | 2001-02-15 | Deutsches Krebsforsch | F¶v¶-Antikörper-Konstrukte |
CA2406993A1 (en) | 2000-03-24 | 2001-09-27 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
US20040220388A1 (en) | 2000-06-30 | 2004-11-04 | Nico Mertens | Novel heterodimeric fusion proteins |
PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
EP1361891A2 (en) * | 2001-02-19 | 2003-11-19 | MERCK PATENT GmbH | Artificial fusion proteins with reduced immunogenicity |
JP4229704B2 (ja) | 2001-04-18 | 2009-02-25 | ダイアックス、コープ | Fc領域ポリペプチドの結合分子 |
CA2462883A1 (en) | 2001-10-12 | 2003-04-17 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
EP1450857B1 (en) | 2001-10-16 | 2010-09-15 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
US20050142539A1 (en) | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
US20070274998A1 (en) | 2002-04-29 | 2007-11-29 | Genpatzz Pharmacogentetics Ag | Novel Bispecific Molecules For Use In Therapy And Diagnosis |
US7351803B2 (en) | 2002-05-30 | 2008-04-01 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
JP2006512050A (ja) | 2002-06-21 | 2006-04-13 | ダイアックス、コープ | 血清タンパク質結合標的特異的リガンドとその同定方法 |
US8044180B2 (en) | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8193318B2 (en) | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス,インコーポレーテッド | FcγRIIB特異的抗体とその利用法 |
US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
EP2364996B1 (en) | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimized FC variants and methods for their generation |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
WO2004062619A2 (en) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF |
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
AU2004255216B2 (en) | 2003-07-01 | 2010-08-19 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
UA86605C2 (ru) | 2004-01-12 | 2009-05-12 | Аплайд Молекьюлер Иволюшн, Инк. | Антитело, которое содержит вариант исходного человеческого fс-участка |
SG151315A1 (en) | 2004-03-31 | 2009-04-30 | Centocor Inc | Human glp-1 mimetibodies, compositions, methods and uses |
WO2005097202A2 (en) | 2004-04-06 | 2005-10-20 | Affibody Ab | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
EP1747237A4 (en) | 2004-04-16 | 2008-05-21 | Macrogenics Inc | SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME |
WO2005110474A2 (en) | 2004-05-10 | 2005-11-24 | Macrogenics, Inc. | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
US7432419B2 (en) | 2004-05-14 | 2008-10-07 | Los Alamos National Security, Llc | Compositions and methods for the treatment of Pierce's disease |
EP1771205B1 (en) | 2004-06-18 | 2016-10-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
BR122018016031B8 (pt) | 2004-08-04 | 2021-07-27 | Applied Molecular Evolution Inc | processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
US20060193849A1 (en) | 2005-02-25 | 2006-08-31 | Antisoma Plc | Biological materials and uses thereof |
US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
EP1868650B1 (en) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
PT2573114T (pt) | 2005-08-10 | 2016-07-13 | Macrogenics Inc | Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos |
EP1820513A1 (en) * | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
WO2008105886A2 (en) | 2006-05-26 | 2008-09-04 | Macrogenics, Inc. | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
KR101799337B1 (ko) | 2007-06-21 | 2017-12-20 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이것의 사용 |
JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
MY164121A (en) | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
EP2272977A1 (en) | 2009-07-08 | 2011-01-12 | Universite Libre De Bruxelles | Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome |
DK2486141T3 (en) | 2009-10-07 | 2018-04-23 | Macrogenics Inc | FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE |
GEP20166442B (en) | 2010-03-04 | 2016-03-10 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CA2807127C (en) * | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
NZ607480A (en) | 2010-08-03 | 2014-10-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US9834615B2 (en) * | 2010-08-16 | 2017-12-05 | Novimmune Sa | Methods for the generation of multispecific and multivalent antibodies |
EP2608803A4 (en) | 2010-08-26 | 2014-01-15 | Abbvie Inc | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
KR20130118892A (ko) | 2010-11-02 | 2013-10-30 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
UY33707A (es) | 2010-11-04 | 2012-05-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2012121775A2 (en) | 2010-12-21 | 2012-09-13 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
UY33826A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
UY33827A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión a media-inmunoglobulina y sus usos |
KR102060389B1 (ko) | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
KR102030531B1 (ko) | 2011-05-21 | 2019-10-10 | 마크로제닉스, 인크. | 탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도 |
UA116479C2 (uk) * | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
-
2013
- 2013-12-20 EP EP13198859.4A patent/EP2840091A1/en not_active Withdrawn
-
2014
- 2014-08-20 JP JP2016536401A patent/JP6581985B2/ja active Active
- 2014-08-20 AU AU2014308907A patent/AU2014308907B2/en not_active Ceased
- 2014-08-20 TN TN2016000052A patent/TN2016000052A1/en unknown
- 2014-08-20 CN CN201480045719.5A patent/CN105658235B/zh active Active
- 2014-08-20 GE GEAP2014014099 patent/GEP20197033B/en unknown
- 2014-08-20 KR KR1020167007407A patent/KR102269584B1/ko active IP Right Grant
- 2014-08-20 CA CA2920117A patent/CA2920117C/en active Active
- 2014-08-20 AP AP2016009082A patent/AP2016009082A0/xx unknown
- 2014-08-20 EA EA201690447A patent/EA036236B1/ru not_active IP Right Cessation
- 2014-08-20 BR BR112016003369A patent/BR112016003369A2/pt not_active Application Discontinuation
- 2014-08-20 MY MYPI2016000329A patent/MY179866A/en unknown
- 2014-08-20 PE PE2016000281A patent/PE20160193A1/es unknown
- 2014-08-20 EP EP14837376.4A patent/EP3035956B1/en active Active
- 2014-08-20 SG SG11201601270WA patent/SG11201601270WA/en unknown
- 2014-08-20 US US14/913,654 patent/US9932400B2/en active Active
- 2014-08-20 UA UAA201602539A patent/UA119329C2/uk unknown
- 2014-08-20 MX MX2016001738A patent/MX2016001738A/es active IP Right Grant
- 2014-08-20 TW TW103128713A patent/TWI675845B/zh active
- 2014-08-20 ES ES14837376T patent/ES2827226T3/es active Active
- 2014-08-20 WO PCT/US2014/051793 patent/WO2015026894A2/en active Application Filing
-
2016
- 2016-02-11 PH PH12016500291A patent/PH12016500291A1/en unknown
- 2016-02-17 CL CL2016000363A patent/CL2016000363A1/es unknown
- 2016-02-22 CR CR20160090A patent/CR20160090A/es unknown
- 2016-02-22 IL IL244238A patent/IL244238B/en active IP Right Grant
- 2016-12-22 HK HK16114614A patent/HK1226000A1/zh unknown
-
2017
- 2017-11-21 US US15/819,423 patent/US10858430B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690447A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ | |
TN2016000046A1 (en) | Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof | |
EA201890443A1 (ru) | Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение | |
CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
PH12016502590B1 (en) | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof | |
EA201690325A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ | |
EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
EA201790719A1 (ru) | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения | |
EA201790961A1 (ru) | Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
MD20170031A2 (ru) | Антитела анти-LAG3 и антигенсвязываюшие фрагменты | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
BR112017009264A2 (pt) | proteína de ligação a epítopo ou um fragmento da mesma e imunoglobulina heterodimérica ou um fragmento da mesma | |
UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
MX2018015265A (es) | Metodos para el uso de moleculas de union a cd32b x cd79b en el tratamiento de enfermedades y trastornos inflamatorios. | |
MX2016014355A (es) | Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado. | |
EA201892096A1 (ru) | Нейтрализующие моноклональные антитела к il-25 и их применение | |
EA202092279A1 (ru) | Антитела к mica и/или micb и их применение | |
EA202092151A1 (ru) | Антитела | |
EA201792460A1 (ru) | Связывающие tigit агенты и варианты их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |